Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-L-selectin monoclonal antibodies - PDL BioPharma

X
Drug Profile

Anti-L-selectin monoclonal antibodies - PDL BioPharma

Alternative Names: Anti-L-selectin monoclonal antibody DREG 200 - PDL BioPharma; Anti-L-selectin monoclonal antibody DREG 55; Aselizumab; BNP 001; DREG 200 - PDL BioPharma; DREG 55; hDREG-200 - PDL BioPharma; hDREG-55; Hu DREG 55; SMART anti-L-selectin antibodies

Latest Information Update: 24 May 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action L-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Shock
  • Discontinued Adult respiratory distress syndrome; Crohn's disease; Psoriasis; Reperfusion injury

Most Recent Events

  • 22 May 2006 No development reported - Preclinical for Shock in USA (unspecified route)
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
  • 18 Aug 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the Skin disorders therapeutic trials section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top